CTL公司*
化学
组织蛋白酶
分子生物学
癌症
癌症研究
生物
组织蛋白酶D
生物化学
细胞毒性T细胞
酶
体外
遗传学
作者
Kelton A. Schleyer,Ben Fetrow,Peter Zannes Fatland,Jun Liu,Maya Chaaban,Biwu Ma,Lina Cui
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2021-07-01
卷期号:81 (13_Supplement): 328-328
被引量:1
标识
DOI:10.1158/1538-7445.am2021-328
摘要
Abstract Cathepsin L (CTL) is a cysteine protease that demonstrates upregulated activity and altered trafficking in various cancers. Its upregulation in many cancers correlates positively with tumor grade while its excessive secretion makes elevated serum levels a possible biomarker for aggressive cancer types. The overlapping substrate specificity of cathepsin family members makes selective detection of activity from a single cathepsin difficult, and CTL activity is particularly difficult to parse from its close homologue CTV and the ubiquitous CTB. This complicates clinical sample assays for CTL activity, which generally rely on simple fluorescent probes lacking specificity for CTL over other cathepsins. We have developed a fluorogenic probe, CTLAP, that is rapidly activated by CTL and displays good selectivity over CTB and CTV, the closest competing analytes for CTL. The novel chemical structure of CTLAP facilitates markedly higher signal generation and improved selectivity for CTL when compared to Z-FR-AMC, the commercial probe commonly used to detect CTL activity in mixed samples. Optimum selectivity for CTL is achieved within 10 min of incubation, suggesting that CTLAP is amenable for rapid detection of CTL, even in the presence of competing cathepsins. Citation Format: Kelton A. Schleyer, Ben Fetrow, Peter Fatland, Jun Liu, Maya Chaaban, Biwu Ma, Lina Cui. Selective fluorogenic probe for rapid detection of cathepsin L activity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 328.
科研通智能强力驱动
Strongly Powered by AbleSci AI